Skip to content

Homeopathic treatment of allergic runny nose

Efficacy of individualized homoeopathic medicines in reducing symptoms of allergic rhino-conjunctivitis in adults: Double-blind, randomized, placebo-controlled trial - NIL

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064437
Enrollment
84
Registered
2024-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified Health Condition 2: H104- Chronic conjunctivitis

Interventions

Intervention1: Individualized homoeopathic medicines in centesimal potencies plus concomitant care: Intervention is planned as administering indicated homoeopathic medicines in centesimal potencies (C
dosage and repetition depending upon the individual requirement of the cases. Patients will be advised to refrain from handling the globules or from eating, drinking, smoking or brushing teeth within

Sponsors

D. N. De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient suffering from Allergic Rhino-conjunctivitis of mild to moderate intensity i.e. presenting the symptoms of Acute exacerbation of chronic Allergic-Rhino-conjunctivitis or Chronic Allergic Rhino-conjunctivitis (perennial and seasonal variety) [ICD 11 CA08.0Z] [ICD 11 9A60.02] 2.Age 18 to 65 years and of either sex or transgender. 3.History of recurrent attack of symptoms of Allergic Rhino-conjunctivitis since childhood 4.Atopic: reactive to inhaled allergens. 5.Elevated Absolute Eosinophil count and elevated Serum IgE level 6.Family history of atopy i.e. similar atopic conditions. 7.Participants having prior experience or knowledge of the treatment. Example- primed to expect ‘homoeopathic aggravation’ and available treatment options for the disease conditions, intimated through Patient Information Sheet.

Exclusion criteria

Exclusion criteria: 1.Nasal abnormalities causing obstruction; e.g. nasal polyps deviated septum. 2.Away from usual environment for more than 1 week during trial. 3.Respiratory infections 4.Patients with risk of developing bronchial asthma 5.Abnormalities of eyes causing severe or gross impairment of visual acuity 6.Patients having cataract or any other gross structural abnormalities of eyes 7.Patient having obstruction of Naso-lachrymal duct 8.Other uncontrolled or unstable systemic or psychiatric diseases and/or infections affecting quality of life. 9.Patients who are too sick for consultation 10.Pregnant and puerperal women, and lactating mothers 11.Substance abuse and/or dependence 12.Self-reported immune-compromised state 13.Oral or parenteral steroids in past 6 months 14.Conventional desensitization in past 6 months 15.Not having any previous history of allergic attack of symptoms of Allergic rhino-conjunctivitis. 16.Previous homoeopathic immunotherapy for Allergic rhinitis or Allergic conjunctivitis within last 6 months. 17.Undergoing homoeopathic treatment for any chronic disease within last 6 months. 18.Uncontrolled hypertension, diabetes, nephritic syndrome, renal insufficiency, uncontrolled hypothyroidism, severe or active liver diseases or any other uncontrolled systemic diseases affecting quality of life or organ failure. 19.Simultaneous participation in any other trial. 20.Vulnerable population- unconscious, non-ambulatory, too sick for consultation, differently abled, terminally and critically ill patient, mentally incompatible patients. 21.Patient not providing written informed consent voluntarily.

Design outcomes

Primary

MeasureTime frame
Mini-Rhino-conjunctivitis Quality of Life Questionnaire (Mini-RQLQ)Timepoint: Baseline, every month, up to 3 months

Secondary

MeasureTime frame
Absolute eosinophil countTimepoint: Baseline, 3 months;RAND Medical Outcome Study Short Form Health Survey 36-symptom score 1.0 (RAND MOS SF 36 1.0)Timepoint: Baseline, every month, up to 3 months;Serum IgETimepoint: Baseline, 3 months

Countries

India

Contacts

Public ContactDr Saima Shamim

D. N. De Homoeopathic Medical College and Hospital

drsaima_7@yahoo.com7059526218

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026